Randomized double-blind placebo-controlled trial of acetyl-L-carnitine for ALS

References

• Beghi E, Mennini T, Bendotti C, Bigini P, Logroscino G, Chiò A, et al. The heterogeneity of amyotrophic lateral sclerosis: a possible explanation of treatment failure. Curr Med Chem. 2007;14:3185–200.
   PubMed Web of Science ®Google Scholar
• Miller RG, Mitchell JD, Lyon M, Moore DH. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). Cochrane Database Syst Rev 2007 ;(1):CD001447.
   Web of Science ®Google Scholar
• Virmani A, Binienda Z. Role of carnitine esters in brain neuropathology. Mol Aspects Med. 2004;25:533–49.
   PubMedGoogle Scholar
• Bigini P, Larini S, Pasquali C, Muzio V, Mennini T. Acetyl-L-carnitine shows neuroprotective and neurotrophic activity in primary culture of rat embryo motor neurons. Neurosci Lett. 2002;329:334–8.
   PubMed Web of Science ®Google Scholar
• Bigini P, Muzio V, de Angelis C, Mennini T. In vitro and in vivo effect of acetyl-L-carnitine on motor neuron degeneration. Neurosci Lett. 1999;52:S18.
   Google Scholar
• Bellingham MC. A review of the neural mechanisms of action and clinical efficiency of riluzole in treating amyotrophic lateral sclerosis: what have we learned in the last decade?CNS Neurosci Ther. 2011;17:4–31.
   PubMed Web of Science ®Google Scholar
• Miller RG, Munsat TL, Swash M, Brooks BR. Consensus guidelines for the design and implementation of clinical trials in ALS. J Neurol Sci. 1999;169:2–12.
   PubMed Web of Science ®Google Scholar
• Cedarbaum JM, Stambler N, Malta E, Fuller C, Hilt D, Thurmond B, et al. The ALSFRS-R: a revised ALS functional rating scale that incorporates assessment of respiratory function. J Neurol Sci. 1999;169:13–21.
   PubMed Web of Science ®Google Scholar
• Medical Research Council. Aids to the investigation of peripheral nerve injuries. War memorandum, 2nd edn. London: HMSO, 1943;7:11–46.
   Google Scholar
• Ware J, Sherbourne C. The MOS 36 item short-form survey (SF-36). I. Conceptual framework and item selection. Med Care. 1992;30:473–83.
   Google Scholar
• COSTART: Coding Symbols for Thesaurus of Adverse Reaction Terms. 5th edn. Rockville, Md: Food and Drug Administration; 1995. Publication FDA/CDER-95/24.
   Google Scholar
• The Italian ALS Study Group. Branched-chain amino acids and amyotrophic lateral sclerosis: a treatment failure?Neurology. 1993;43:2466–70.
   PubMed Web of Science ®Google Scholar
• Beghi E, Chiò A, Inghilleri M, Mazzini L, Micheli A, Mora G, et al. A randomized controlled trial of recombinant interferon beta-1a in ALS. Neurology. 2000;54:469–74.
   PubMed Web of Science ®Google Scholar
• Steiner T. Branched-chain amino acid in ALS. The European trial. In: Clifford RF, editor. New evidence MND/ALS research. London: Smith-Gordon; 1991. pp. 315–6.
   Google Scholar
• Messina P, Beghi E. Modelling drop-outs in amyotrophic lateral sclerosis. Contemp Clin Trials. 2012;33:218–22.
   PubMed Web of Science ®Google Scholar
• Cudkowicz M, Bozik ME, Ingersoll E, Miller R, Mitsumoto H, Shefner J, et al. The effects of dexpramipexole (KNS-760704) in individuals with amyotrophic lateral sclerosis. Nat Med. 2011;17:1652–6.
   PubMed Web of Science ®Google Scholar
• Rudnicki SA, Berry JD, Ingersoll E, Archibald D, Cudkowicz ME, Kerr DA, Dong Y. Dexpramipexole effects on functional decline and survival in subjects with amyotrophic lateral sclerosis in a phase II study: subgroup analysis of demographic and clinical characteristics. Amyotroph Lateral Scler. 2013;25:44–51.
   Google Scholar
• Kimura F, Fujimura C, Ishida S, Nakajima H, Furutama D, Uehara H, et al. Progression rate of ALSFRS-R at time of diagnosis predicts survival time in ALS. Neurology. 2006;66: 265–7.
   PubMed Web of Science ®Google Scholar
• Bigini P, Muzio V, Pasquali C, Larini S, Ghirardi O, Mennini T. Acetyl-L-carnitine effect on motor neuron disease. Amyotroph Lateral Scler Other Motor Neuron Disord. 2001:2:153.
   PubMedGoogle Scholar
• Ramirez C, Piemonte ME, Callegaro D, Da Silva HC. Fatigue in amyotrophic lateral sclerosis: frequency and associated factors. Amyotroph Lateral Scler. 2008;9:75–80.
   PubMed Web of Science ®Google Scholar
• McElhiney MC, Rabkin JG, Gordon PH, Goetz R, Mitsumoto H. Prevalence of fatigue and depression in ALS patients and change over time. J Neurol Neurosurg Psychiatry. 2009;80:1146–9.
   PubMed Web of Science ®Google Scholar
• Lo Coco D, La Bella V. Fatigue, sleep, and nocturnal complaints in patients with amyotrophic lateral sclerosis. Eur J Neurol. 2012;19:760–2013.
   PubMed Web of Science ®Google Scholar
• Tomassini V, Pozzilli C, Onesti E, Pasqualetti P, Marinelli F, Pisani A, et al. Comparison of the effects of acetyl-L- carnitine and amantadine for the treatment of fatigue in multiple sclerosis: results of a pilot, randomized, double-blind, crossover trial. J Neurol Sci. 2004;218:103–8.
   PubMed Web of Science ®Google Scholar
• Plioplys AV, Plioplys S. Amantadine and L-carnitine treatment of chronic fatigue syndrome. Neuropsychobiology. 1997;35:16–23.
   PubMed Web of Science ®Google Scholar
• Hart AM, Wilson AD, Montovani C, Smith C, Johnson M, Terenghi G, et al. Acetyl-L-carnitine: a pathogenesis based treatment for HIV-associated antiretroviral toxic neuropathy. AIDS. 2004;18:1549–60.
   PubMed Web of Science ®Google Scholar
• Bianchi G, Vitali G, Caraceni A, Ravaglia S, Capri G, Cundari S, et al. Symptomatic and neurophysiological responses of paclitaxel- or cisplatin-induced neuropathy to oral acetyl-L-carnitine. Eur J Cancer. 2005;41:1746–50.
   PubMed Web of Science ®Google Scholar
• de Grandis D. Tolerability and efficacy of acetyl-L-carnitine in patients with peripheral neuropathies: a short-term, open multicentre study. Clin Drug Invest. 1998;15:73–9.
   PubMedGoogle Scholar
• Gramignano G, Lusso MO, Madeddu C, Massa E, Serpe R, Deiana L, et al. Efficacy of L-carnitine administration on fatigue, nutritional status, oxidative stress, and related quality of life in 12 advanced cancer patients undergoing anticancer therapy. Nutrition. 2006;22:136–45.
   PubMed Web of Science ®Google Scholar
• Spagnoli LG, Palmieri G, Mauriello A, Vacha GM, D’Iddio S, Giorcelli G, et al. Morphometric evidence of the trophic effect of L-carnitine on human skeletal muscle. Nephron. 1990;55:16–23.
   PubMed Web of Science ®Google Scholar
• Marin B, Desport JC, Kajeu P, Jesus P, Nicolaud B, Nicol M, et al. Alteration of nutritional status at diagnosis is a prognostic factor for survival of amyotrophic lateral sclerosis patients. J Neurol Neurosurg Psychiatry. 2011;82:628–34.
   PubMed Web of Science ®Google Scholar
• Desport JC, Preux PM, Truong TC, Vallat JM, Sautereau D, Couratier P. Nutritional status is a prognostic factor for survival in ALS patients. Neurology. 1999;53:1059–63.
   PubMed Web of Science ®Google Scholar
• Norris FH Jr, Calanchini PR, Fallat RJ, Panchari S, Jewett B. The administration of guanidine in amyotrophic lateral sclerosis. Neurology. 1974;24:721–8.
   PubMed Web of Science ®Google Scholar
• Anonymous. Acetyl-L-carnitine monograph. Alternative Med Rev. 2010;15:76–83.
   PubMedGoogle Scholar